This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
More than half of health system and health plan executives say AI is an immediate priority, and 73% are increasing their investments in the technology, a new C-suite survey finds. | More than half of health system and health plan executives say AI is an immediate priority, and 73% are increasing their investments in the technology, a new C-suite survey finds.
Public health and infectious disease experts offered their perspectives on the 2024 US bird flu outbreak and its potential of becoming a greater public health crisis.
Schrödinger CEO Ramy Farid wants you to know that his company isn’t an AI company…but he’ll call it that if you want to. The company, founded in 1990, started out by making software that used the basic laws of physics to laboriously and exactly predict how molecules will interact with each other in space. Those calculations, rooted in the field of computational physics, needed lots of expensive and time-consuming computing power to run, and many people abandoned those t
A subcutaneous version of Merck’s Keytruda was as effective as the infused version in a late-stage study, but the company won’t be the first to market.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Adderall is a controlled prescription medication commonly used to treat attention deficit hyperactivity disorder ( ADHD ). It is also approved by the Food and Drug Administration (FDA) to promote wakefulness in people with narcolepsy , a sleep disorder. The standard, immediate-release Adderall is usually taken two or three times per day, while extended-release Adderall XR is taken once daily.
Investigators said there is an imperative to optimize medication utilization and explore the consequences of medication burden on treatment outcomes in patients with long COVID.
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart disease — the first new treatment for the condition in over five years and the company’s first significant commercial product. The drug, known scientifically as acoramidis, will be sold by BridgeBio under the brand name Attruby.
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart disease — the first new treatment for the condition in over five years and the company’s first significant commercial product. The drug, known scientifically as acoramidis, will be sold by BridgeBio under the brand name Attruby.
With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in a bid to boost production for a long-approved transplant treatment and a | Sanofi has unveiled a 40 million euro investment at its Lyon Gerland biomanufacturing site in France. The cash infusion will help bolster local production of the company’s polyclonal antibody Thymoglubulin for kidney transplant rejection, as well as expected future capacity needs for the type 1 diab
When Makena, a drug designed to prevent preterm births, hit the market in 2011 at $1,500 per dose, it drew rife backlash. The drug was based on an active ingredient that had been available for many years at a much lower cost. Confronted with the public outcry, the FDA took an unusual step: It allowed pharmacies to continue making their own copies of the drug through the practice of pharmacy compounding, selling it at a fraction of Makena’s price.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
The company is looking to score an FDA nod for its investigational therapy that targets a molecule linked to Guillain-Barré syndrome and other autoimmune diseases.
Articles in Issue 5 of European Pharmaceutical Review include: FOREWORD ICH Q6(R1): test criteria and specifications Dave Elder David P Elder Consultancy CELL & GENE THERAPY How automation and digital technologies will unlock the full potential of advanced therapies Dr Stephen Ward CGT Catapult Hydrogel encapsulation: unlocking the potential of cell therapies for targeted treatments Dr Stephen Harrington and Francis Karanu Likarda SUSTAINABILITY Transitioning to digital product information t
Although more pharmaceutical companies are tailoring their business models to focus on low-income countries, a new analysis finds that overall industry efforts remain limited and patient access continues to suffer as a result. Notably, momentum has stalled in reaching licensing deals that are designed to make lower-cost generic drugs available in parts of the world where brand-name medicines are unaffordable, and few companies have pursued technology transfer agreements.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
California has detected the country’s first case of a new mpox strain that is spreading from person to person. The infected individual had recently traveled from Eastern Africa, where multiple countries are battling transmission of this virus. The individual was treated in a health facility in San Mateo County and is in isolation at home, the California Department of Public Health announced in a statement released Saturday.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
This month, the Chalmers University of Technology in Sweden have published the results of a study demonstrating that resistant bacteria, when paired with material equipped with antibacterial peptides, can regain susceptibility to antibiotics. The study, conducted in a laboratory environment, concluded that antibiotics – such as oxacillin – could achieve an increase in their bactericidal […] The post Antibacterial peptides instrumental in efficiency against resistant bacteria appeared first
Premenstrual Dysphoric Disorder is considered a psychiatric disorder and is associated with moderate to severe physical, affective, and behavioral symptoms.
Merck said a new formulation of the best-selling drug, Keytruda, appears to deliver similar blood levels of the medicine when it is given as a shot as when it is given intravenously. For Merck, the new under-the-skin, or subcutaneous, formulation of Keytruda could represent a major way of holding on to a larger share of Keytruda’s $25 billion in annual sales than would otherwise occur when the medicine’s U.S. patent expires in 2028.
LONDON — The stacks of brightly colored disposable e-cigarettes, touting flavors like cotton candy ice and greengrape melon and often looming over the not-dissimilar-looking candy displays, have become a commonplace sight in convenience stores in both the U.S. and the U.K. But here, they’re on their way out.
Table of Contents Sr# Headings 1 Introduction 2 What Is Display Advertising? 3 Why Display Advertising Matters in Pharma 4 Key Benefits of Display Advertising 5 Targeting: Reaching the Right Audience 6 Personalization in Display Ads 7 Case Study: Successful Pharma Display Campaigns 8 Choosing the Right Platforms 9 Metrics to Track for ROI Success 10 Regulatory Challenges and Solutions 11 The Role of Branded Drugs in Display Ads 12 Creative Best Practices for Display Ads 13 Aligning Display Ads w
The battle over prescription drug discounts offered to hospitals under a federal program escalated as Sanofi became the third pharmaceutical company to disclose plans to change the way it will make payments. In a letter sent to hospitals and clinics on Friday, Sanofi indicated that certain hospitals covered by the 340B Drug Discount Program would receive credits for medicines ordered at full price from a wholesaler.
Increased global capacity for surveillance could help monitor seasonal influenza to reduce the risk of vaccine mismatch and inform effective interventions.
Oura is partnering with medical device maker Dexcom to integrate data from glucose biosensors with the Oura Ring, which tracks sleep, heart rate and activity. | Oura is partnering with medical device maker Dexcom to integrate data from glucose biosensors with the Oura Ring.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content